Join our daily newsletter At The Bell to receive exclusive market insights
- OncoSil Medical (OSL) publishes the final results of the PanCO clinical study for its OncoSil device
- OncoSil is a targeted radioactive isotope implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound
- No radiation-related serious Adverse Events (AEs) were reported in the PanCO study
- The median progression-free survival of PanCO study participants who received chemotherapy plus OncoSil was 9.3 months and local PFS was 9.8 months
- OncoSil Medical shares were up 10 per cent to 4.3 cents at 1220pm AEDT
OncoSil Medical (OSL) publishes the final results of the PanCO clinical study for its OncoSil device.
OSL said the results demonstrate the safety and efficacy benefits of the OncoSil device in combination with chemotherapy for the treatment of patients with unresectable locally advanced pancreatic cancer.
OncoSil is a targeted radioactive isotope implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.
Treatment with the OncoSil is intended to deliver more concentrated and localised beta radiation compared to external beam radiation.
PanCO is an international, multi-centre, single-arm, prospective clinical study of intra-tumoral OncoSil.
No radiation-related serious Adverse Events (AEs) were reported in the PanCO study.
There is no evidence that the incidence of severe AEs changed after OncoSil implantation.
The main efficacy endpoint of the PanCO study is the proportion of participants with local disease control at 16 weeks, achieved in 90.5 per cent of the patients.
In 13 of the PanCO study participants who received OncoSil, partial responses to treatment were demonstrated, with a disease control rate of 100 per cent as the best response.
Nearly one-in-four of the PanCO study participants with unresectable cancers proceeded to surgical resection with curative intent following treatment with chemotherapy plus OncoSil.
There are additional patients who received chemotherapy plus OncoSil who became resectable, but they did not proceed to surgery for medical reasons or patient choice.
The median progression-free survival (PFS) of PanCO study participants who received chemotherapy plus OncoSil was 9.3 months and local PFS was 9.8 months.
The median overall survival was 15.5 months.
OncoSil Medical shares were up 10.2 per cent to 4.3 cents at 1220 AEDT.
